Department of Gastroenterology, Nowon Eulji Medical Center, Eulji University, Seoul, Korea.
Division of Hepatobiliary & Pancreatic Surgery, Department of Surgery, Asan Medical Center, Seoul, Korea.
Dig Endosc. 2018 Jul;30(4):508-515. doi: 10.1111/den.13041. Epub 2018 Apr 3.
Fully covered self-expandable metal stent (FCSEMS) placement has been tried for pancreatic ductal strictures in chronic pancreatitis. However, the long-term outcome of this procedure remains unknown. The present study aimed to investigate the procedural and long-term outcomes of FCSEMS placement in patients with benign refractory pancreatic ductal strictures.
Between August 2011 and September 2015, 18 patients underwent endoscopic treatment with FCSEMS for benign refractory pancreatic ductal stricture. Technical success, clinical success, radiological success, and adverse events were assessed.
Stent placement was successful in all patients (technical success rate, 100%). Reduction in pain score of >50% was achieved in 15 of the 18 patients (clinical success rate, 83.3%). In all patients, stents could easily be removed at a median of 7.5 months (interquartile range [IQR], 6-13.6) after their insertion. FCSEMS migration did not develop in any patient. Ductal stricture was improved in 15 patients (radiological success rate, 83.3%). After definite stent removal, 13 of the 15 (86.7%) patients who had responded to pancreatic stenting maintained the response during follow up (median of 47.3 months; IQR, 7.4-57.1).
FCSEMS placement appears to be safe and effective for the treatment of benign refractory pancreatic ductal strictures as it can provide persistent improvement in the stricture in long-term follow up.
在慢性胰腺炎中,已尝试使用全覆膜自膨式金属支架(FCSEMS)治疗胰管狭窄。然而,该治疗方法的长期效果尚不清楚。本研究旨在探讨 FCSEMS 置入术治疗良性难治性胰管狭窄患者的手术过程和长期效果。
2011 年 8 月至 2015 年 9 月,18 例患者因良性难治性胰管狭窄接受了内镜下 FCSEMS 治疗。评估技术成功率、临床成功率、影像学成功率和不良事件。
所有患者的支架置入均成功(技术成功率 100%)。18 例患者中有 15 例(83.3%)疼痛评分降低>50%(临床成功率)。所有患者的支架中位取出时间为置入后 7.5 个月(四分位距 [IQR] 6-13.6),易于取出。没有患者出现支架迁移。15 例患者(83.3%)的胰管狭窄得到改善。在明确取出支架后,15 例(86.7%)对胰管支架有反应的患者在随访期间(中位时间为 47.3 个月;IQR 7.4-57.1)保持了反应。
FCSEMS 置入术治疗良性难治性胰管狭窄安全有效,可在长期随访中持续改善狭窄。